Key result
Atorvastatin reduces high glucose-induced collagen IV expression by ~28% in human endothelial cells.
Why the study?
The effects of statins on endothelial cell extracellular matrix production and related enzymes following exposure to high glucose are not known.
Does atorvastatin attenuate high glucose-induced extracellular matrix production in human endothelial cells?
Does atorvastatin attenuate high glucose-induced extracellular matrix production in human endothelial cells?
Atorvastatin attenuates high glucose-induced extracellular matrix production in human endothelial cells, providing a potential mechanism for statin-induced atherosclerotic plaque regression.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for statin effects on diabetic endothelial matrix; should not change practice without in vivo confirmation.
BACKGROUND: Statins are known to enhance atherosclerotic plaque stability through influences on extracellular matrix homeostasis. Net matrix production reflects the relative balance of matrix production and degradation through enzymes such as matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitor of MMP (TIMPs). The effects of statins on endothelial cell production of these parameters following co-exposure with a proatherogenic stimulus such as high glucose are not known. METHODS: Human endothelial cells were exposed for 72 h to 5 mm (control) or 25 mm (high) glucose +/- atorvastatin (1 micromol/l). Extracellular matrix homeostasis was assessed by measuring matrix metalloproteinase (MMP)-2 secretion, tissue inhibitor of MMP (TIMP)-1 and -2 secretion and net collagen IV production. Results were expressed as percentage +/- SEM of control values. RESULTS: Exposure to high glucose increased cellular collagen IV expression to 190.1 +/- 11.7% (P < 0.0001) of control levels. No change in MMP-2 secretion (111.6 +/- 5.2%; P > 0.05) was observed but both TIMP-1 and TIMP-2 expression were increased to 136.3 +/- 6.4% and 144.0 +/- 27.5%, respectively (both P < 0.05). The presence of atorvastatin in high glucose conditions reduced collagen IV expression to 136.1 +/- 20.6%. This was paralleled by increased secretion of MMP-2 to 145.8 +/- 7.8% (P < 0.01), increased TIMP-2 expression to 208.0 +/- 21.3% (P < 0.005 compared with high glucose) but no change in TIMP-1 expression (155.1 +/- 14.6%) compared with high glucose alone. The presence of atorvastatin in control conditions did not affect levels of collagen IV expression (114.5 +/- 13.2%). CONCLUSIONS: Endothelial cell exposure to high glucose was associated with a MMP/TIMP profile that increased extracellular matrix production which was attenuated by concurrent exposure to atorvastatin. Consequently, a mechanism by which the atherosclerotic plaque regression that is observed in patients taking these drugs has been demonstrated.
No takes yet. Share an insight, caveat, or question.
McGinn et al. (2004) studied Atherosclerotic plaque stability. Atorvastatin vs. High glucose alone was evaluated on Collagen IV expression (percentage of control). Atorvastatin attenuated high glucose-induced extracellular matrix production in human endothelial cells, reducing collagen IV expression from 190.1% to 136.1% of control levels.
Synapse has enriched 10 related papers. Consider them for comparative context: